Trimetazidine-Biokom mv 35mg pills with modif. high coated n60
Condition: New product
996 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Trimetazidine
Release form
Pills
Composition
1 tablet contains: Active ingredient: Trimetazidine dihydrochloride 35 mg.
Pharmacological effect
A tool that normalizes the energy metabolism of cells subjected to hypoxia or ischemia. Prevents a decrease in the intracellular content of ATP, ensures the normal functioning of membrane ion channels, transmembrane transfer of potassium and sodium ions and preservation of cellular homeostasis. Trimetazidine slows down fatty acid oxidation by selectively inhibiting long-chain 3-ketoacetyl-CoA thiolase, which leads to an increase in glucose oxidation and restoration of the conjugation between glycolysis and oxidative decarboxylation and, as has been shown, protects myocardium from ischemia. Switching fatty acid oxidation to glucose oxidation underlies the antianginal action of trimetazidine. Experimental studies on animals have shown that trimetazidine supports the energy metabolism of the heart and neurosensory organs during periods of ischemic episodes, reduces the amount of intracellular acidosis and the degree of changes in transmembrane ion flow arising during ischemia, reduces the level of migration and infiltration of polynuclear neutrophils in ischemic and reperfusion , reduces the size of myocardial damage, and has no effect on hemodynamics.
Pharmacokinetics
Trimetazidine is rapidly and almost completely absorbed by the intestinal mucosa. Bioavailability is 90%. Cmax is reached within 2 hours and is (after a single oral dose of 20 mg of trimetazidine) about 55 ng / ml. Vd - 4.8 l / kg. Easily passes through histohematogenous barriers. Plasma protein binding is 16%. T1 / 2 - 4.5-5 hours. Excreted by the kidneys (about 60% - unchanged).
Indications
Long-term treatment of coronary artery disease: prevention of strokes (monotherapy or as part of combination therapy) treatment of cochleo-vestibular disorders of ischemic nature (including dizziness, tinnitus, hearing loss) chorioretinal vascular disorders with an ischemic component.
Contraindications
Pregnancy, lactation (breastfeeding), hypersensitivity to trimetazidine.
Dosage and administration
Is taken orally at a dose of 40-60 mg / day, the multiplicity of reception 2-3 times / day. The duration of therapy is determined individually, depending on the clinical situation.